Hangzhou, China, Oct. 10, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, today announced that it has received a notification letter from the Nasdaq Stock Market LLC (“Nasdaq”) granting the Company an additional 180-calendar-day period to regain compliance with the minimum bid price requirement pursuan ...

The newest Republican candidate for Massachusetts governor plans to use the fortune he reaped in part from Johnson & Johnson’s acquisition of his medical-device company to outflank his opponents and defend his tenure at the heart-pump maker https://t.co/cPYFzipwJE ...

Core Insights - Elutia Inc. has appointed Guido J. Neels to its Board of Directors, who will also serve on the audit committee, following the resignation of W. Matthew Zuga and Maybelle Jordan from the Board [1][2] Company Overview - Elutia is a pioneer in drug-eluting biomatrix technologies, focusing on improving compatibility between medical devices and patients [4] - The company aims to humanize medicine, allowing patients to thrive without compromise, particularly in the context of a growing population needing implantable technologies [4] Leadership Experience - Guido J. Neels brings over 40 years of experience in the medical technology sector, having held various managerial and strategic roles [2] - Neels is currently an Operating Partner at EW Healthcare Partners and has been instrumental in building EW's medical device investment practice [2] - His previous roles include Chief Operating Officer at Guidant Corporation, where he oversaw multiple operating units and was responsible for sales operations and corporate communications [3] Strategic Direction - Neels expressed his honor in joining Elutia during a pivotal moment for the company, emphasizing the potential of Elutia's technology to improve patient outcomes and drive innovation in breast reconstruction [4] - The company is focused on leveraging its drug-eluting biomatrix technology to build significant shareholder value, especially following the recent divestiture of its EluPro business [2]

HOUSTON, TX, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, is excited to announce its participation in the upcoming 2025 Maxim Growth Summit on October 22nd at The Hard Rock Hotel NYC. This event brings together industry experts, innovators, and thought leaders to explore the latest trends and advancements across several industries. Attendees will have the opportunity t ...

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Dive Brief: Zimmer Biomet has launched two orthopedic devices with Paragon 28, the foot and ankle specialist it bought for $1.1 billion early this year.  The new products, which Zimmer reported Wednesday, add treatments for a type of shinbone break and hindfoot injuries to the company’s portfolio. Introducing the devices continues Zimmer’s efforts to maintain Par ...

MINNEAPOLIS, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today published Inspire V clinical outcomes data from its Singapore clinical study as well as the Company’s limited market release in the United States including single site experience at two leading centers. These data will be presented at ...

About Insulet Corporation: Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a ...

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulseâ"¢ technology using its proprietary Nanosecond Pulsed Field Ablationâ"¢ (nanosecond PFA or nsPFAâ"¢) energy, today announced late-breaking clinical study results from the nPulseâ"¢ Cardiac Surgical System first-in-human feasibility study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting in Copenhagen, Denmark. The feasibility study is intended to assess the initial s. ...

Core Insights - Therma Bright Inc. has appointed Michael Raimondo, a healthcare veteran with 30 years of experience, to its Board of Directors, transitioning from an advisory role [1][5] - Raimondo has a proven track record in sales negotiations, having secured over $500 million in sales contracts, and has held significant leadership positions at Abbott [2][4] - The company aims to leverage Raimondo's expertise to enhance market penetration and drive sales growth for its flagship medical device, Venowave, which addresses vascular issues [5] Company Overview - Therma Bright Inc. focuses on developing and partnering in advanced diagnostic and medical device technologies, providing innovative solutions for healthcare challenges [6] - The company trades on multiple exchanges, including TSXV, OTCQB, and FSE [6] Strategic Focus - Raimondo's primary focus will be on building a high-performance internal sales team and expanding market reach through strategic partnerships with medical device resellers [5] - The company highlights the significant market potential for Venowave, particularly for the 900,000 individuals affected by deep vein thrombosis annually in the U.S. [5]

BURLINGTON, Mass., Oct. 09, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its third quarter 2025 financial results on Thursday, November 6, 2025, after the market close. The company has scheduled a conference call for 5:00 PM EST the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access t ...